MS and the B cell controversy

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 2, 2011, Pages 231-238

  Cross, Anne H ^a   Waubant, Emmanuelle ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody; B lymphocyte; Multiple sclerosis; Rituximab; Therapy

Indexed keywords

AUTOANTIBODY; GADOLINIUM; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYELIN; PLACEBO; RITUXIMAB;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BRAIN TISSUE; BRONCHITIS; CEREBROSPINAL FLUID; CHILL; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; GASTROENTERITIS; HUMAN; HYPOTENSION; IMMUNOGENICITY; INFECTION; INFLUENZA; LYMPHOID TISSUE; MONOTHERAPY; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHODGKIN LYMPHOMA; NONHUMAN; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PATHOGENESIS; PLASMA CELL; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; RESPIRATORY FAILURE; REVIEW; RHINOPHARYNGITIS; RIGOR; SINUSITIS; THYROID TUMOR; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOCYTE DEPLETION; LYMPHOID TISSUE; MULTIPLE SCLEROSIS; MYELIN PROTEINS; PLASMA CELLS;

EID: 78650179904     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.07.020     Document Type: Review

References (74)

1. Kabat E.A., Glusman M., Knaub V. Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am. J. Med. 1948, 4:653-662.
2. Zamvil S.S., Mitchell D.J., Moore A.C., Kitamura K., Steinman L., Rothbard J.B. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 1986, 324:258-260.
3. Prineas J.W. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 1979, 203:1123-1125.
4. Magliozzi R., Howell O., Vora A., Serafini B., Nicholas R., Puopolo M., Reynolds R., Aloisi F. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130:1089-1104.
5. Mizoguchi A., Bhan A.K. A case for regulatory B cells. J. Immunol. 2006, 176:705-710.
6. Prineas J.W., Raine C.S. Electron microscopy and immunoperoxidase studies of early multiple sclerosis lesions. Neurology 1976, 26:29-32.
7. Prineas J.W., Wright R.G. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab. Invest. 1978, 38:409-421.
8. Esiri M.M. Immunoglobulin-containing cells in multiple-sclerosis plaques. Lancet 1977, 2:478.
9. van Dinther-Janssen A.C., Hofland L., Scheper R.J. Specific plasma cell accumulation in antigen-induced chronic inflammation in the guinea pig peritoneal cavity. Int. Arch. Allergy Appl. Immunol. 1986, 79:14-18.
10. Lanzavecchia A., Bernasconi N., Traggiai E., Ruprecht C.R., Corti D., Sallusto F. Understanding and making use of human memory B cells. Immunol. Rev. 2006, 211:303-309.
11. Kindler V., Zubler R.H. Memory, but not naive, peripheral blood B lymphocytes differentiate into Ig-secreting cells after CD40 ligation and costimulation with IL-4 and the differentiation factors IL-2, IL-10, and IL-3. J. Immunol. 1997, 159:2085-2090.
12. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
13. Barnett M.H., Parratt J.D., Cho E.S., Prineas J.W. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann. Neurol. 2009, 65:32-46.
14. Barnett M.H., Prineas J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 2004, 55:458-468.
15. Breij E.C., Brink B.P., Veerhuis R., van den Berg C., Vloet R., Yan R., Dijkstra C.D., van der Valk P., Bo L. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 2008, 63:16-25.
16. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004, 14:164-174.
17. Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 2006, 6:205-217.
18. Magalhaes R., Stiehl P., Morawietz L., Berek C., Krenn V. Morphological and molecular pathology of the B cell response in synovitis of rheumatoid arthritis. Virchows Arch. 2002, 441:415-427.
19. Cepok S., Rosche B., Grummel V., Vogel F., Zhou D., Sayn J., Sommer N., Hartung H.P., Hemmer B. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005, 128:1667-1676.
20. Kuenz B., Lutterotti A., Ehling R., Gneiss C., Haemmerle M., Rainer C., Deisenhammer F., Schocke M., Berger T., Reindl M. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One 2008, 3:e2559.
21. Cepok S., Jacobsen M., Schock S., Omer B., Jaekel S., Boddeker I., Oertel W.H., Sommer N., Hemmer B. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 2001, 124:2169-2176.
22. Sharief M.K., Hentges R., Ciardi M. Intrathecal immune response in patients with the post-polio syndrome. N. Engl. J. Med. 1991, 325:749-755.
23. Sharief M.K., Thompson E.J. Intrathecal immunoglobulin M synthesis in multiple sclerosis. Relationship with clinical and cerebrospinal fluid parameters. Brain 1991, 114(Pt 1A):181-195.
24. Sharief M.K., Hentges R. Importance of intrathecal synthesis of IgD in multiple sclerosis. A combined clinical, immunologic, and magnetic resonance imaging study. Arch. Neurol. 1991, 48:1076-1079.
25. Villar L.M., Gonzalez-Porque P., Masjuan J., Alvarez-Cermeno J.C., Bootello A., Keir G. A sensitive and reproducible method for the detection of oligoclonal IgM bands. J. Immunol. Methods 2001, 258:151-155.
26. Walsh M.J., Tourtellotte W.W., Roman J., Dreyer W. Immunoglobulin G, A, and M-clonal restriction in multiple sclerosis cerebrospinal fluid and serum-analysis by two-dimensional electrophoresis. Clin. Immunol. Immunopathol. 1985, 35:313-327.
27. Trotter J.L.R., R.S. Human cerebrospinal fluid immunology. Cerebrospinal Fluid 1989, 179-226. Martinus Nijhoff, Amsterdam. R. Brumbach, R. Herndon (Eds.).
28. Tourtellotte W.W., Parker J.A. Multiple sclerosis: correlation between immunoglobulin-G in cerebrospinal fluid and brain. Science 1966, 154:1044-1045.
29. Avasarala J.R., Cross A.H., Trotter J.L. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch. Neurol. 2001, 58:2044-2045.
30. Zeman A.Z., Kidd D., McLean B.N., Kelly M.A., Francis D.A., Miller D.H., Kendall B.E., Rudge P., Thompson E.J., McDonald W.I. A study of oligoclonal band negative multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1996, 60:27-30.
31. Rinker J.R., Trinkaus K., Cross A.H. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology 2006, 67:1288-1290.
32. Olsson J.E., Link H. Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remissions. Arch. Neurol. 1973, 28:392-399.
33. Villar L.M., Sadaba M.C., Roldan E., Masjuan J., Gonzalez-Porque P., Villarrubia N., Espino M., Garcia-Trujillo J.A., Bootello A., Alvarez-Cermeno J.C. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J. Clin. Invest. 2005, 115:187-194.
34. Joseph F.G., Hirst C.L., Pickersgill T.P., Ben-Shlomo Y., Robertson N.P., Scolding N.J. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J. Neurol. Neurosurg. Psychiatry 2009, 80:292-296.
35. Rudick R.A., Medendorp S.V., Namey M., Boyle S., Fischer J. Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains. Mult. Scler. 1995, 1:150-155.
36. Idiman E., Ozakbas S., Dogan Y., Kosehasanogullari G. The significance of oligoclonal bands in multiple sclerosis: relevance of demographic and clinical features, and immunogenetic backgrounds. J. Neuroimmunol. 2009, 212:121-124.
37. Owens G.P., Bennett J.L., Lassmann H., O'Connor K.C., Ritchie A.M., Shearer A., Lam C., Yu X., Birlea M., DuPree C., Williamson R.A., Hafler D.A., Burgoon M.P., Gilden D. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann. Neurol. 2009, 65:639-649.
38. Cruz M., Olsson T., Ernerudh J., Hojeberg B., Link H. Immunoblot detection of oligoclonal anti-myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis. Neurology 1987, 37:1515-1519.
39. Aarli J.A., Aparicio S.R., Lumsden C.E., Tonder O. Binding of normal human IgG to myelin sheaths, glia and neurons. Immunology 1975, 28:171-185.
40. Xiao B.G., Linington C., Link H. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J. Neuroimmunol. 1991, 31:91-96.
41. Banki K., Colombo E., Sia F., Halladay D., Mattson D.H., Tatum A.H., Massa P.T., Phillips P.E., Perl A. Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis. J. Exp. Med. 1994, 180:1649-1663.
42. Esposito M., Venkatesh V., Otvos L., Weng Z., Vajda S., Banki K., Perl A. Human transaldolase and cross-reactive viral epitopes identified by autoantibodies of multiple sclerosis patients. J. Immunol. 1999, 163:4027-4032.
43. Wucherpfennig K.W., Catz I., Hausmann S., Strominger J.L., Steinman L., Warren K.G. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J. Clin. Invest. 1997, 100:1114-1122.
44. Warren K.G., Catz I. Autoantibodies to myelin basic protein within multiple sclerosis central nervous system tissue. J. Neurol. Sci. 1993, 115:169-176.
45. O'Connor K.C., Appel H., Bregoli L., Call M.E., Catz I., Chan J.A., Moore N.H., Warren K.G., Wong S.J., Hafler D.A., Wucherpfennig K.W. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J. Immunol. 2005, 175:1974-1982.
46. Raine C.S., Cannella B., Hauser S.L., Genain C.P. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann. Neurol. 1999, 46:144-160.
47. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., Dilitz E., Deisenhammer F., Reindl M. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. 2003, 349:139-145.
48. Mantegazza R., Cristaldini P., Bernasconi P., Baggi F., Pedotti R., Piccini I., Mascoli N., La Mantia L., Antozzi C., Simoncini O., Cornelio F., Milanese C. Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association. Int. Immunol. 2004, 16:559-565.
49. Kuhle J., Pohl C., Mehling M., Edan G., Freedman M.S., Hartung H.P., Polman C.H., Miller D.H., Montalban X., Barkhof F., Bauer L., Dahms S., Lindberg R., Kappos L., Sandbrink R. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N. Engl. J. Med. 2007, 356:371-378.
50. Rauer S., Euler B., Reindl M., Berger T. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J. Neurol. Neurosurg. Psychiatry 2006, 77:739-742.
51. McLaughlin K.A., Chitnis T., Newcombe J., Franz B., Kennedy J., McArdel S., Kuhle J., Kappos L., Rostasy K., Pohl D., Gagne D., Ness J.M., Tenembaum S., O'Connor K.C., Viglietta V., Wong S.J., Tavakoli N.P., de Seze J., Idrissova Z., Khoury S.J., Bar-Or A., Hafler D.A., Banwell B., Wucherpfennig K.W. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J. Immunol. 2009, 183:4067-4076.
52. Acarin N., Rio J., Fernandez A.L., Tintore M., Duran I., Galan I., Montalban X. Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis. Acta Neurol. Scand. 1996, 93:99-103.
53. Arnon R., Crisp E., Kelley R., Ellison G.W., Myers L.W., Tourtellotte W.W. Anti-ganglioside antibodies in multiple sclerosis. J. Neurol. Sci. 1980, 46:179-186.
54. Endo T., Scott D.D., Stewart S.S., Kundu S.K., Marcus D.M. Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. J. Immunol. 1984, 132:1793-1797.
55. Freedman M.S., Laks J., Dotan N., Altstock R.T., Dukler A., Sindic C.J. Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event. Mult. Scler. 2009, 15:422-430.
56. Schwarz M., Spector L., Gortler M., Weisshaus O., Glass-Marmor L., Karni A., Dotan N., Miller A. Serum anti-Glc(alpha1, 4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis. J. Neurol. Sci. 2006, 244:59-68.
57. Genain C.P., Nguyen M.H., Letvin N.L., Pearl R., Davis R.L., Adelman M., Lees M.B., Linington C., Hauser S.L. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J. Clin. Invest. 1995, 96:2966-2974.
58. Stashenko P., Nadler L.M., Hardy R., Schlossman S.F. Characterization of a human B lymphocyte-specific antigen. J. Immunol. 1980, 125:1678-1685.
59. Martin Mdel P., Cravens P.D., Winger R., Kieseier B.C., Cepok S., Eagar T.N., Zamvil S.S., Weber M.S., Frohman E.M., Kleinschmidt-Demasters B.K., Montine T.J., Hemmer B., Marra C.M., Stuve O. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch. Neurol. 2009, 66:1016-1020.
60. Hainsworth J.D., Litchy S., Barton J.H., Houston G.A., Hermann R.C., Bradof J.E., Greco F.A. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 2003, 21:1746-1751.
61. Hainsworth J.D., Litchy S., Burris H.A., Scullin D.C., Corso S.W., Yardley D.A., Morrissey L., Greco F.A. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 2002, 20:4261-4267.
62. Cross A.H., Stark J.L., Lauber J., Ramsbottom M.J., Lyons J.A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 2006, 180:63-70.
63. Piccio L., Naismith R.T., Trinkaus K., Klein R.S., Parks B.J., Lyons J.A., Cross A.H. Changes in B and T lymphocytes and chemokines with rituximab treatment in multiple sclerosis. Arch. Neurol. 2010, 67:707-714.
64. Monson N.L., Cravens P.D., Frohman E.M., Hawker K., Racke M.K. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch. Neurol. 2005, 62:258-264.
65. Stuve O., Cepok S., Elias B., Saleh A., Hartung H.P., Hemmer B., Kieseier B.C. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch. Neurol. 2005, 62:1620-1623.
66. Bar-Or A., Calabresi P.A., Arnold D., Markowitz C., Shafer S., Kasper L.H., Waubant E., Gazda S., Fox R.J., Panzara M., Sarkar N., Agarwal S., Smith C.H. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann. Neurol. 2008, 63:395-400.
67. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
68. Bar-Or A., Fawaz L., Fan B., Darlington P.J., Rieger A., Ghorayeb C., Calabresi P.A., Waubant E., Hauser S.L., Zhang J., Smith C. Abnormal B cell cytokine responses: a trigger of T-cell-mediated disease in MS?. Ann. Neurol. 2010, 67:452-462.
69. Hawker K., O'Connor P., Freedman M.S., Calabresi P.A., Antel J., Simon J., Hauser S., Waubant E., Vollmer T., Panitch H., Zhang J., Chin P., Smith C.H. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 2009, 66:460-471.
70. Ruhstaller T.W., Amsler U., Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?. Ann. Oncol. 2000, 11:374-375.
71. Rodriguez M., Miller D.J., Lennon V.A. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996, 46:538-545.
72. Niehaus A., Shi J., Grzenkowski M., Diers-Fenger M., Archelos J., Hartung H.P., Toyka K., Bruck W., Trotter J. Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination. Ann. Neurol. 2000, 48:362-371.
73. Duddy M., Niino M., Adatia F., Hebert S., Freedman M., Atkins H., Kim H.J., Bar-Or A. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 2007, 178:6092-6099.
74. Naismith R.T., Piccio L., Lyons J.A., Lauber J., Tutlam N.T., Parks B.J., Trinkaus K., Song S.K., Cross A.H. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010, 74:1860-1867.